Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.
Lilly believes it has two promising new molecules for diabetes and obesity. But which to choose – and might toxicity yet scupper one or both?